Purple Biotech to Present IM1240 Data in Barcelona
The company will showcase research on its tri-specific antibody at the upcoming 38th EORTC-NCI-AACR Symposium.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Are you optimistic about the current pace of new cancer immunotherapy drug development?
Purple Biotech announced it will deliver an oral presentation on its IM1240 antibody at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain. The presentation will detail the efficacy of the treatment in human tumor models.
Why it matters
This presentation provides insight into the progress of the CAPTN-3 platform as Purple Biotech works toward human testing. It offers researchers a look at how the company's conditional CD3 masking approach performs in treatment-resistant cases.
The study evaluates the pharmacokinetic and safety performance of the CAPTN-3 conditional CD3 masking approach in treatment-resistant human tumor models. This research precedes a planned initiation of first-in-human clinical studies in 2027.
The players
Purple Biotech
This is a biotechnology company headquartered in Rehovot, Israel, that specializes in the development of cancer therapies.
Amir Horowitz
He is the scheduled presenter for the abstract titled ENA26-0137 regarding the IM1240 antibody.
The details
Amir Horowitz is scheduled to present the findings during a plenary session at the symposium. The session will focus on the technical capabilities of the antibody and data regarding its safety profile.
Timeline
The 38th EORTC-NCI-AACR Symposium runs from November 18-20, 2026.
The oral presentation is scheduled for November 20, 2026, at 15:00 CET.
Purple Biotech plans to initiate a first-in-human clinical study in 2027.
The Big Picture
The presentation marks the latest data disclosure for the CAPTN-3 platform as it transitions from laboratory tumor models toward clinical application. This move aligns with the company's broader objective to demonstrate the viability of its tri-specific antibody technology.
The upcoming presentation offers transparency into the experimental safety and efficacy profiles of the IM1240 antibody for patients interested in emerging cancer treatments. Final data release will help clarify the timeline for potential human clinical trials.
The takeaway
This disclosure highlights the technical development phase of new tri-specific antibody therapies currently undergoing preclinical validation. Investors and the medical community can monitor these results to gauge the feasibility of the platform's 2027 clinical timeline.
What happens next
The oral presentation of abstract ENA26-0137 is scheduled for November 20, 2026, at 15:00 CET.
Further reading
For more on the latest research in the field, explore our Cancer section.
More information
Access additional details via the Purple Biotech company information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Are you optimistic about the current pace of new cancer immunotherapy drug development?
